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INTRODUCTION
Epithelial ovarian cancer (EOC) has the highest death rate
among gynecologic malignancies throughout the world, pri-
marily because most patients are diagnosed with advanced
stage disease. The standard treatment consists of cytoreduc-
tive surgery followed by induction chemotherapy with a tax-
ane/platinum combination. Despite an initial excellent res-
ponse to chemotherapy, the disease subsequently recurs in
most patients and their long-term prognosis is dismal. For
patients with optimally debulked stage III ovarian cancer,
the median progression-free survival (PFS) is 21 months,
with a median overall survival (OS) of 57 months (1). Even
patients who attain a complete clinical response (cCR) after
primary therapy, as defined by the absence of symptoms, nor-
mal examination, serum CA 125 concentration below 35 U/
mL and imaging analyses showing no evidence of disease,
have a median PFS from completion of therapy of about 21
months (2, 3). 
Most patients who attain cCR to primary treatment receive
no additional chemotherapy, although the majority will require
multiple salvage regimens due to tumor recurrence. Attempts
to improve the clinical outcome of EOC patients included
the identification of new first-line regimens which are able
to induce higher cCR rates and effective treatments to con-
solidate or maintain the response achieved by first-line che-
motherapy (4). Consolidation therapy uses one or more of the
multiple chemotherapeutic agents known to be active in recur-
rent disease (5, 6). One of these agents, hexamethylmelamine
(HMM), which has been used to treat recurrent ovarian can-
cer for many years, is well tolerated (7-11) and is associated
with prolonged PFS and OS in the Phase II setting (12). Lit-
tle is known, however, about outcomes of consolidation ther-
apy in advanced EOC patients; and there have been no com-
parison studies of HMM consolidation therapy in these pa-
tients. We therefore assessed the efficacy of HMM consoli-
dation therapy in advanced EOC patients.
MATERIALS AND METHODS
Patients (n=102) with histologically confirmed advanced
(stage III or IV) EOC and documented cCR following front-
line platinum-based therapy who had been treated at Asan
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Hexamethylmelamine as Consolidation Treatment for Patients with
Advanced Epithelial Ovarian Cancer in Complete Response after
First-Line Chemotherapy
The aim of this study was to assess the efficacy of consolidation therapy with hex-
amethylmelamine (HMM) in patients with advanced epithelial ovarian cancer (EOC).
Patients treated at our hospital between January 1997 and November 2006 and in
documented clinical complete response from advanced ovarian cancer following
front-line platinum-based therapy were retrospectively analyzed. The patients treated
with HMM were compared to the patients of matched counterpart without consoli-
dation therapy. Of 102 patients enrolled, 49 were treated with HMM and 53 received
no consolidation treatment. For patients with HMM and observed patients, the mean
age were 54.6 and 55.6 yr; the distribution of stage was similar (P=0.977); the opti-
mal surgery was performed in 36 (73.5%) and 44 (83%) (P=0.336); the recurrence
rate were 27 (55.1%) and 33 (62.3%) (P=0.463); and the median progression-free
survival were 38 months and 21 months for patients with HMM and observed patients
(P=0.235). No treatment-related adverse events were reported during the follow-
up period. Although this study failed to show the significant survival benefit of con-
solidation therapy with HMM in patients with advanced EOC, we consider that our
study can contribute data to investigate the effectiveness of consolidation therapy
in epithelial ovarian cancer.
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were enrolled. All patients had WHO performance status of
2 or less (Karnofsky index >60) and adequate bone marrow
(white blood cell count [WBC] >3.0×109/L and platelet
count >100×109/L), kidney (serum creatinine <120 μ M/
L), and liver (liver enzymes ≥2×upper normal limit) func-
tion.
Patients (n=49) treated with oral HMM (altretamine) con-
solidation therapy were retrospectively assessed and compared
to the untreated patients (n=53). Each patient in the former
group received 260 mg/m2/day HMM for 14 consecutive days
of each 28-day cycle, with a maximum of 12 cycles. Treat-
ment was stopped early due to disease progression, unaccept-
able toxicity, or withdrawal of patient compliance. The pati-
ent was followed for recurrence of measurable disease as defined
by the study protocol. Patients were also followed by physi-
cal examination, pelvic examination, complete blood counts,
blood chemistries and CA-125 concentration every 3 months
for the first 2 yr and every 6 months thereafter until disease
progression, death, or loss to follow-up. 
Among clinical and pathological characteristics of patients,
optimal debulking was defined as residual tumor <1 cm, sub-
optimal debulking as residual tumor ≥1 cm. Serum CA-
125 concentration was measured 6 weeks after initiation of
the front-line chemotherapy. Toxicity was graded according
to Gynecologic Oncology Group (GOG) criteria. PFS was
estimated from the date of study registration to the date of
clinically proven recurrence.
Data analysis was performed using SPSS (version 12.0). The
chi-square test, Student’s t-test were used to compare clini-
cal and pathologic characteristics of patient groups. PFS anal-
yses were performed using the Kaplan-Meier method and
log-rank test. We estimated the parameters in the Cox pro-
portional hazard model using PFS as a dependent variable,
CA-125 concentration and debulking status as independent
variables, and recurrence as a censoring variable. For all sta-
tistical tests, the level of significance was P<0.05.
RESULTS
Of the 102 patients with documented cCR from advanced
EOC following front-line platinum-based therapy, 49 received
HMM consolidation treatment and 53 received no consoli-
dation treatment. The two groups were similar in age, debulk-
ing status, histological type, stage, CA-125 concentration 6
weeks after initiation of first-line therapy, and recurrence rate
(Table 1). 
Of the 49 HMM-treated patients who received at least one
cycle of oral altretamine, 14 patients did ≤3 cycles, 4 patients
did 4 to 5 cycles of HMM. Among the patients who received
6-12 cycles (n=31), 12 patients did 12 cycles of HMM.
Although the median PFS of the HMM-treated group (38
months; 95% confidence interval [CI] 16-60 months) was
longer than that of the untreated group (21 months; 95% CI
16-26 months), the difference was not significant (P=0.235)
(Fig. 1).
Of patients with optimal debulked disease (residual tumor
<1 cm), those who received consolidation treatment had a
median PFS of 41 months (95% CI 25-57 months), where-
as those who received no treatment had a median PFS of 25
months (95% CI 19-31 months), but there was no signifi-
cant difference (P=0.333) (Fig. 2). Of patients with subop-
timal debulked disease (residual tumor ≥1 cm), median PFS
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Parameters HMM treated Untreated P value
No. of patients 49 53
Mean age at diagnosis (yr) 54.6 55.6 0.672
FIGO stage 0.977
IIIA 2 (4.1%) 3 (5.7%)
IIIB 5 (10.2%)  4 (7.5%)
IIIC 38 (77.6%) 41 (77.4%)
IV 4 (8.2%) 5 (9.4%)
Histological type 0.508
Serous 33 (67.3%) 40 (75.5%)
Mucinous 7 (14.3%) 8 (15.1%)
Endometrioid 4 (8.2%) 2 (3.8%)
Clear cell 3 (6.1%) 2 (3.8%)
Adenocarcinoma 1  (2.0%) 0 
Other 1 (2.0%) 1 (1.9%)
Debulking status 0.336
Optimal (residual <1 cm) 36 (73.5%) 44 (83%)
Suboptimal (residual ≥1 cm) 13 (26.5%) 9 (17%)
Recurrence 0.463
No 22 (44.9%) 20 (37.7%)
Yes 27 (55.1%) 33 (62.3%)
Mean (standard error) CA-125  20.49 (2.5) 18.96 (1.9) 0.626
at 6 weeks after initiation of 
first-line therapy, IU/mL
Table 1. Clinical and pathological characteristics of HMM-treat-
ed and -untreated patients
Fig. 1. Progression-free survival of HMM-treated and -untreated
patients.
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P=0.235of those who did and did not receive HMM were 16 months
(95% CI 10-22 months) and 16 months (95% CI 12-20 mon-
ths), respectively (P=0.204) (Fig. 3). Using Cox’s proportion-
al hazards model, we found that serum CA-125 concentration
6 weeks after initiation of first-line therapy, which means just
before the 3rd cycle of adjuvant chemotherapy (P<0.0001),
stage (P=0.005), and debulking status (P=0.038) were sig-
nificant prognostic factors for PFS (Table 2). Gastrointestinal
toxicity was the prominent feature in our study group. Four
patients discontinued consolidation therapy due to grade 4
toxicity. But most patients with HMM were tolerable dur-
ing the follow-up period.
DISCUSSION
Cytoreductive surgery followed by induction chemother-
apy with a taxane/platinum combination is currently accept-
ed as the standard regimen for advanced EOC. Despite excel-
lent responses to first-line chemotherapy, most patients with
advanced ovarian cancers who achieve cCR relapse after a me-
dian time of 18-24 months (13-15). Among attempts made
to improve the clinical outcome of EOC patients is maintain-
ing the response achieved by first-line chemotherapy. Main-
tenance therapy can include cytotoxic chemotherapy, radia-
tion therapy, and/or biological therapy. Several trials have
assessed maintenance therapy with single-agent HMM, epiru-
bicin, topotecan, or paclitaxel in patients responsive to first-
line platinum-based chemotherapy (2, 16-18). 
HMM (altretamine) is a synthetic, cytotoxic, antineoplastic,
s-triazine derivative that can be taken orally. Its exact mech-
anism of action is unknown, although chemically it resem-
bles alkylating agents (19, 20). Vergote et al. reported a 14%
response rate of HMM as a single agent in 50 patients with
pltinum-resistant disease. And oral altretamine 260 mg/m2/
day was given for 14 days every 4 weeks for six cycles to pa-
tients with FIGO stage III EOC who obtained a clinical res-
ponse following platinum-based therapy (12). To date, how-
ever, there have been no trials comparing HMM with no treat-
ment in patients with advanced EOC.
The dosage of HMM used in this study was 260 mg/m2/
day for 14 days every 4 weeks, for a maximum 12 cycles; and
median follow-up was 3.2 yr. 37 of 49 (75.6%) patients with
HMM did not receive maximum 12 cycles. HMM therapy
for patients received less than 6 cycles (n=18) were caused
by a progression of disease, and severe gastrointestinal toxic-
ity. For patients receiving 6 or more cycles of HMM (n=31)
the reasons of discontinuation were patient’s desire of discon-
tinuation of consolidation therapy due to poor compliance
with gastrointestinal discomfort and a loss of follow-up. 
Our study failed to show the statistical significance in the
median PFS of the HMM-treated group (Fig. 1). The main
reason of this results might be a small number of our study.
Prospective randomized trials in larger numbers of patients
are clearly warranted.
Serum CA-125 is a marker frequently used in evaluating
the clinical situation in ovarian cancer patients, and the rate
of decline in serum CA-125 during primary chemotherapy
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Fig. 2. Progression-free survival of patients with optimal debulked
disease (residual tumor <1 cm), treated or untreated with HMM. 
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P=0.333
Fig. 3. Progression-free survival of patients with suboptimal de-
bulked disease (residual tumor ≥1 cm), treated or untreated with
HMM. 
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P=0.204
Variable SE
Chi-
square
P
value
HR 95% CI
CA-125 at 8 weeks 0.007 23.387 <0.0001 1.035 1.021; 1.049
Debulking status 0.301 4.321 0.038 1.870 1.036; 3.374
Age 0.012 0.00 0.992 1.000 0.977; 1.024
Histological type 0.124 0.418 0.519 0.923 0.725; 1.176
Grade 0.223 1.22 0.727 1.085 0.687; 1.713
Stage 0.289 7.598 0.005 2.267 1.287; 3.993
Table 2. Factors predictive of progression free survival, as deter-
mined by Cox models
SE, standard error; HR, hazard ratio; CI, confidence interval.has been an important prognostic factor in several multivari-
ate analyses (21). Moreover, postoperative serum CA-125 con-
centration is an independent prognostic factor in patients
with invasive ovarian cancer (22). Reduction in serum CA-
125 over the first two cycles of platinum-based chemothera-
py is an independent predictor of survival in patients with
suboptimal stage III or IV ovarian cancer; patients without
significant declines had a particularly poor prognosis (23).
In agreement with these findings, our study results showed
that CA-125 concentration 6 weeks after initiation of first-
line chemotherapy was prognostic for PFS. 
We also found that debulking status was a prognostic of
PFS in patients with advanced EOC. Our finding is in agree-
ment with that large residual disease after initial surgery is
the strongest prognostic variable for tumor recurrence (14,
24, 25). Of our 102 patients, 80 had optimal cytoreductive
surgery (residual <1 cm), whereas 22 had suboptimal surgery
(residual ≥1 cm). Although all 102 patients achieved cCR
following first-line chemotherapy, those with optimal surgery
had a better prognosis than those with suboptimal surgery.
The ultimate aim of consolidation therapy is to improve
clinical outcome, including prolonged survival rate and bet-
ter quality of life in patients with EOC. Few studies have
investigated consolidaton therapy in patients with advanced
EOC. Although our study were retrospective analysis and
failed to show the prolonging PFS in patients with advanced
EOC by consolidation therapy with HMM, we consider that
our study can contribute data to investigate the effectiveness
of consolidation therapy in epithelial ovarian cancer.
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